These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21939545)

  • 1. Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism.
    Aragonès G; Alonso-Villaverde C; Pardo-Reche P; Rull A; Beltrán-Debón R; Rodríguez-Gallego E; Fernández-Sender L; Camps J; Joven J
    BMC Med Genet; 2011 Sep; 12():120. PubMed ID: 21939545
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Srinivasan R; Padmapriyadarsini C; Ramesh K; Sanjeeva GN; Reddy D; Suresh E; Kumar R; Sathyamoorthy P; Swaminathan S; Shet A
    AIDS Res Hum Retroviruses; 2021 Feb; 37(2):92-100. PubMed ID: 33115242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients.
    Bonnet E; Bernard J; Fauvel J; Massip P; Ruidavets JB; Perret B
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):169-71. PubMed ID: 18240956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of single nucleotide polymorphisms with dyslipidemia in antiretroviral exposed HIV patients in a Ghanaian population: A case-control study.
    Obirikorang C; Acheampong E; Quaye L; Yorke J; Amos-Abanyie EK; Akyaw PA; Anto EO; Bani SB; Asamoah EA; Batu EN
    PLoS One; 2020; 15(1):e0227779. PubMed ID: 31929604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
    Arnedo M; Taffé P; Sahli R; Furrer H; Hirschel B; Elzi L; Weber R; Vernazza P; Bernasconi E; Darioli R; Bergmann S; Beckmann JS; Telenti A; Tarr PE;
    Pharmacogenet Genomics; 2007 Sep; 17(9):755-64. PubMed ID: 17700364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms of the ApoE (Apolipoprotein E) gene and their influence on dyslipidemia in HIV-1-infected individuals.
    Suwalak T; Srisawasdi P; Puangpetch A; Santon S; Koomdee N; Chamnanphon M; Charoenyingwattana A; Chantratita W; Sukasem C
    Jpn J Infect Dis; 2015; 68(1):5-12. PubMed ID: 25420659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipids profile among ART-naïve HIV infected patients and men who have sex with men in China: a case control study.
    Wang Q; Ding H; Xu J; Geng W; Liu J; Guo X; Kang J; Li X; Jiang Y; Shang H
    Lipids Health Dis; 2016 Sep; 15(1):149. PubMed ID: 27600391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation.
    Guardiola M; Ferré R; Salazar J; Alonso-Villaverde C; Coll B; Parra S; Masana L; Ribalta J
    Clin Chem; 2006 Oct; 52(10):1914-9. PubMed ID: 16887900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy.
    Rodríguez-Gallego E; Gómez J; Domingo P; Ferrando-Martínez S; Peraire J; Viladés C; Veloso S; López-Dupla M; Beltrán-Debón R; Alba V; Vargas M; Castellano AJ; Leal M; Pacheco YM; Ruiz-Mateos E; Gutiérrez F; Vidal F; Rull A;
    Atherosclerosis; 2018 Jun; 273():28-36. PubMed ID: 29677628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.
    Hiransuthikul N; Hiransuthikul P; Kanasook Y
    Southeast Asian J Trop Med Public Health; 2007 Jan; 38(1):69-77. PubMed ID: 17539249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: the relevance of apolipoprotein E genotypes and immunological status.
    Malavazi I; Abrão EP; Mikawa AY; Landgraf VO; da Costa PI
    Clin Chem Lab Med; 2004 May; 42(5):525-32. PubMed ID: 15202789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
    Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
    HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
    Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
    Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
    van der Valk M; Kastelein JJ; Murphy RL; van Leth F; Katlama C; Horban A; Glesby M; Behrens G; Clotet B; Stellato RK; Molhuizen HO; Reiss P;
    AIDS; 2001 Dec; 15(18):2407-14. PubMed ID: 11740191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.
    Egaña-Gorroño L; Martínez E; Cormand B; Escribà T; Gatell J; Arnedo M
    AIDS; 2013 Feb; 27(4):529-38. PubMed ID: 23262498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients.
    Fauvel J; Bonnet E; Ruidavets JB; Ferrières J; Toffoletti A; Massip P; Chap H; Perret B
    AIDS; 2001 Dec; 15(18):2397-406. PubMed ID: 11740190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
    Petit JM; Duong M; Masson D; Buisson M; Duvillard L; Bour JB; Brindisi MC; Galland F; Guiguet M; Gambert P; Portier H; Vergès B
    Eur J Clin Invest; 2004 Aug; 34(8):569-75. PubMed ID: 15305892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
    Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F;
    Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype.
    Shahmanesh M; Jaleel H; DeSilva Y; Ross JD; Caslake M; Cramb R
    Sex Transm Infect; 2001 Aug; 77(4):283-6. PubMed ID: 11463929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: a systematic review and meta-analysis.
    Nduka C; Sarki A; Uthman O; Stranges S
    Int J Cardiol; 2015 Nov; 199():307-18. PubMed ID: 26241636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.